<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_DyafAXd">Evaluating multiple surrogate markers with censored data</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Layla</forename><surname>Parast</surname></persName>
							<email>parast@rand.org</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Statistics Group , RAND Corporation , Santa Monica , California</note>
								<orgName type="department">Statistics Group</orgName>
								<orgName type="institution">RAND Corporation</orgName>
								<address>
									<settlement>Santa Monica</settlement>
									<region>California</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tianxi</forename><surname>Cai</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Biostatistics , Harvard University , Boston , Massachusetts</note>
								<orgName type="department">Department of Biostatistics</orgName>
								<orgName type="institution">Harvard University</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lu</forename><surname>Tian</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Biomedical Data Science , Stanford University , Stanford , California</note>
								<orgName type="department">Department of Biomedical Data Science</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>California</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Statistics Group , RAND Corporation , 1776 Main Street , Santa Monica , CA 90401.</note>
								<orgName type="department">Statistics Group</orgName>
								<orgName type="institution">RAND Corporation</orgName>
								<address>
									<addrLine>1776 Main Street</addrLine>
									<postCode>90401.</postCode>
									<settlement>Santa Monica</settlement>
									<region>CA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">National Institute of Diabetes and Diges- tive and Kidney Diseases ,</note>
								<orgName type="institution">National Institute of Diabetes and Diges- tive and Kidney Diseases</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_Y7aECAq">Evaluating multiple surrogate markers with censored data</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">2685E09FDE02D67707445959E9798E6D</idno>
					<idno type="DOI">10.1111/biom.13370</idno>
					<note type="submission">Received: 23 December 2019 Accepted: 1 September 2020</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T14:00+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_Ew6k58B">double robust</term>
					<term xml:id="_GaEZAjU">inverse probability weighting</term>
					<term xml:id="_Z9hnE7X">surrogate marker</term>
					<term xml:id="_qWJrSSA">survival</term>
					<term xml:id="_Cvs9gy9">treatment effect 1</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_hGZxnQt"><p xml:id="_59WCdY8"><s xml:id="_tZud5g5">The utilization of surrogate markers offers the opportunity to reduce the length of required follow-up time and/or costs of a randomized trial examining the effectiveness of an intervention or treatment.</s><s xml:id="_YnW86T5">There are many available methods for evaluating the utility of a single surrogate marker including both parametric and nonparametric approaches.</s><s xml:id="_3kRZzmB">However, as the dimension of the surrogate marker increases, a completely nonparametric procedure becomes infeasible due to the curse of dimensionality.</s><s xml:id="_ufx243G">In this paper, we define a quantity to assess the value of multiple surrogate markers in a time-to-event outcome setting and propose a robust estimation approach for censored data.</s><s xml:id="_G5nAff6">We focus on surrogate markers that are measured at some landmark time,  0 , which occurs earlier than the end of the study.</s><s xml:id="_JRbenPK">Our approach is based on a dimension reduction procedure with an option to incorporate weights to guard against potential misspecification of the working model, resulting in three different proposed estimators, two of which can be shown to be double robust.</s><s xml:id="_sCVhumQ">We examine the finite sample performance of the estimators under various scenarios using a simulation study.</s><s xml:id="_AR4u3zP">We illustrate the estimation and inference procedures using data from the Diabetes Prevention Program (DPP) to examine multiple potential surrogate markers for diabetes.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="782.362"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Vz4pHHA">INTRODUCTION</head><p xml:id="_bgUgxNt"><s xml:id="_ZN4hMvy">Testing for a treatment effect using a surrogate marker in place of a primary outcome can potentially decrease study length and costs.</s><s xml:id="_g5nNWaH">However, identifying valid surrogate markers is an ongoing challenge and its complexity is reflected in the rich statistical and clinical research on this topic over the past 30 years <ref type="bibr" target="#b33">(Prentice, 1989;</ref><ref type="bibr" target="#b11">Burzykowski et al., 2005;</ref><ref type="bibr" target="#b43">Weir and Walley, 2006;</ref><ref type="bibr" target="#b40">VanderWeele, 2013)</ref>.</s><s xml:id="_sYSx4bW">While there are many available statistical methods to evaluate surrogate markers, these methods tend to focus on settings where there is only one potential marker being evaluated <ref type="bibr" target="#b18">(Freedman et al., 1992;</ref><ref type="bibr" target="#b26">Lin et al., 1997;</ref><ref type="bibr" target="#b25">Li et al., 2001;</ref><ref type="bibr" target="#b42">Wang and Taylor, 2002;</ref><ref type="bibr" target="#b13">Conlon et al., 2014)</ref>.</s><s xml:id="_AHdAYdJ">In practice, there are often multiple potential surrogate markers and it is reasonable to consider whether the group of markers together may serve as useful surrogate marker information <ref type="bibr" target="#b31">(Parast et al., 2015;</ref><ref type="bibr" target="#b6">Athey et al., 2016;</ref><ref type="bibr" target="#b38">Van der Elst et al., 2019)</ref>.</s><s xml:id="_nTCBttJ">For example, in studies examining interventions to prevent diabetes where the primary outcome is a diabetes diagnosis, it may be the case that fasting plasma glucose, or Hemoglobin A1c, or body mass index (BMI) may all be relatively poor surrogate markers when evaluated individually, but that these three measurements together may be useful.</s></p><p xml:id="_UYYsDPP"><s xml:id="_bbC2XAb">Though the majority of statistical methodological development has focused on the single surrogate marker setting, some work has explored the multiple marker setting.</s></p><p xml:id="_3Zf5WQv"><s xml:id="_6mcnSYW">A straightforward and intuitive approach proposed by <ref type="bibr" target="#b18">Freedman et al. (1992)</ref> is to simply fit a regression model predicting the primary outcome with only the treatment indicator as a predictor variable, and then fit a second model that includes the multiple surrogate markers as additive effects, and to examine the resulting change in the regression coefficient for treatment.</s><s xml:id="_q6bsV8z">If the magnitude of the regression coefficient for treatment decreases dramatically, then the set of surrogate markers would be said to be explaining a large proportion of the treatment effect.</s><s xml:id="_Pdu3U3U">While easy to implement, there are a number of limitations with this approach <ref type="bibr" target="#b40">(VanderWeele, 2013;</ref><ref type="bibr" target="#b31">Parast et al., 2015)</ref>.</s><s xml:id="_2Vt95KE">Alternatively, <ref type="bibr" target="#b31">Parast et al. (2015)</ref> proposed a two-stage approach, whereby the multiple markers are first combined using a working model and then a nonparametric kernel smoothing approach is used to evaluate the utility of the resulting combination.</s><s xml:id="_aH8j9Pc">More recently, <ref type="bibr" target="#b38">Van der Elst et al. (2019)</ref> extended the concepts of the adjusted association and individual causal association, previously developed in the univariate surrogate setting by <ref type="bibr" target="#b5">Alonso et al. (2015)</ref> and <ref type="bibr" target="#b12">Buyse and Molenberghs (1998)</ref>, to the multivariate surrogate setting under the assumption that the outcome and surrogates follow a multivariate normal distribution.</s><s xml:id="_65pxwJC"><ref type="bibr" target="#b22">Huang and Gilbert (2011)</ref> proposed several quantities to evaluate multiple markers when the outcome is binary using a semiparametric likelihood method and <ref type="bibr" target="#b19">Gabriel et al. (2015)</ref> extended this approach to a time-toevent outcome setting under a special Weibull model.</s><s xml:id="_UMJ4pT8"><ref type="bibr" target="#b44">Xu and Zeger (2001)</ref> suggest quantifying how much precision is gained in terms of predicting the outcome when using multiple surrogate markers versus only one surrogate or no surrogate information via a joint latent model for the primary outcome and surrogate markers conditional on treatment.</s><s xml:id="_Cme3RPV"><ref type="bibr" target="#b34">Price et al. (2018)</ref> recently proposed an approach to identify an optimal surrogate marker, which may be a function of multiple surrogates, such that this optimal surrogate captures as much information about the primary outcome as possible.</s><s xml:id="_CtWctpd">Their estimation approach involves an initial super-learner estimator of this optimal surrogate followed by an update using targeted maximum likelihood estimation.</s></p><p xml:id="_g9psm33"><s xml:id="_ExB5jAU">However, these available approaches are not able to accommodate a time-to-event outcome subject to censoring and/or tend to generally rely on strict model assumptions.</s><s xml:id="_D8K42AZ">While continuous and binary outcomes remain important, the clinical settings where there is the most demand for valid surrogate markers are those where the outcome is the time to an event.</s><s xml:id="_RttaqR4">For example, the majority of clinical trials examining treatments for chronic diseases such as diabetes, cancer, and cardiovascular disease focus on time-to-event outcomes such as time until diagnosis, disease progression, or death.</s><s xml:id="_bDRBZMX">Reliance on model assumptions can result in bias when these models do not hold <ref type="bibr" target="#b31">(Parast et al., 2015)</ref>.</s><s xml:id="_QcAgk2m">The complex relationship between event outcomes and multiple surrogate markers given treatment, can be particularly difficult to model parametrically.</s><s xml:id="_TRtQhth">Admittedly, the desire to completely avoid any model assumptions is difficult when considering multiple markers because as the dimension of  (the potential surrogate markers) increases, a completely nonparametric procedure is generally infeasible due to the curse of dimensionality <ref type="bibr" target="#b35">(Robins and Ritov, 1997)</ref>.</s></p><p xml:id="_FSwgHyJ"><s xml:id="_MeKwRaa">In this paper, we define a quantity to assess the value of multiple surrogate markers and propose a robust estimation framework based on a two-stage smoothing procedure, which involves the use of a working model, followed by an option to incorporate weights to guard against misspecification of the working model.</s><s xml:id="_pQnsND3">Our framework results in three different proposed estimators, two of which have a double-robust property.</s><s xml:id="_nsvNZsD">We derive the asymptotic properties of our proposed estimators and develop inference procedures.</s><s xml:id="_ScsSRvM">We examine the finite sample performance of our proposed estimators in a simulation study, compare our proposed estimators to model-based estimators, and illustrate the resulting estimates and inference procedures by examining multiple markers for diabetes using data from the Diabetes Prevention Program (DPP) study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2" xml:id="_aRcQffV">PROPORTION OF TREATMENT EFFECT EXPLAINED BY MULTIPLE SURROGATE MARKERS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1" xml:id="_29H55fK">Notation</head><p xml:id="_EsrqBmN"><s xml:id="_eRnZbvq">Let  ∈ {, } be the binary treatment indicator and we assume throughout that subjects are randomly assigned to either treatment group  or  at baseline, and that treatment A is hypothesized to be the more beneficial treatment with respect to delaying or preventing the occurrence of the primary outcome.</s><s xml:id="_DmNWYqq">Let  denote the time to the occurrence of the primary outcome, death for example, and  = ( 1 ,  2 , … ,   )  denote the vector of  surrogate markers measured at a given time  0 .</s><s xml:id="_93uqhjZ">Let  () and  () denote the counterfactual event time and surrogate marker measurements under treatment  =  for  ∈ {, }.</s><s xml:id="_t5CVFEh">In practice, we only observe (, ) = ( () ,  () ) or ( () ,  () ) depending on whether  =  or .</s><s xml:id="_MMrRE6F">Throughout, we define the treatment effect, Δ(), as the treatment difference in survival rates at time  &gt;  0 ,</s></p><formula xml:id="formula_0">Δ(𝑡) = 𝐸{𝐼(𝑇 (𝐴) &gt; 𝑡)} -𝐸{𝐼(𝑇 (𝐵) &gt; 𝑡)} = 𝑃(𝑇 (𝐴) &gt; 𝑡) -𝑃(𝑇 (𝐵) &gt; 𝑡),</formula><p xml:id="_eu4YjDG"><s xml:id="_kgrvGVk">where (⋅) is the indicator function.</s><s xml:id="_GDqJKky">For individuals who are censored or experience the primary outcome before  0 , we assume that their  information is not available.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2" xml:id="_N9PWFdx">Proportion of treatment effect explained by multiple surrogate markers</head><p xml:id="_ATUCFME"><s xml:id="_NRFybKy">Our goal is to quantify the proportion of the treatment effect on ( &gt; ) that is explained by the treatment effect on surrogate marker information available at  0 .</s><s xml:id="_S5KBKv2">Parallel to the approach in <ref type="bibr" target="#b30">Parast et al. (2017)</ref>, we define surrogate marker information at time  0 as a combination of the observed information on ( &gt;  0 ) and the observed  at  0 , denoted by   0 = { ()  0 ,  = , }, where  ()  0 = { () ∧  0 ,  () ( () &gt;  0 )}.</s><s xml:id="_vzgk4GG">This allows us to incorporate observable primary outcome information up to  0 and is more reasonable than discarding those who experience the primary event by  0 when evaluating surrogate marker information.</s><s xml:id="_sbCr7a5">Throughout, we assume that  () ⟂  () ( () &gt;  0 ) | { () , ( () &gt;  0 )} (A1)</s></p><p xml:id="_egDqxf5"><s xml:id="_MbTg5zH"> () ⟂  () ( () &gt;  0 ) | { () , ( () &gt;  0 )}, (A2) which are needed for identifiability and causal interpretation.</s><s xml:id="_MyuKwgY">With information on   0 , we define the residual treatment effect as:</s></p><formula xml:id="formula_1">Δ 𝐒 (𝑡, 𝑡 0 ) = 𝐸 { 𝐼(𝑇 (𝐴) &gt; 𝑡) -𝐼(𝑇 (𝐵) &gt; 𝑡) | 𝐐 (𝐴) 𝑡 0 = 𝐐 (𝐵) 𝑡 0 } ,<label>(1)</label></formula><p xml:id="_8Y5JqHQ"><s xml:id="_5fT9cgk">which is the hypothetical risk difference at time  if the surrogate information at  0 of the two groups was the same.</s></p><p xml:id="_VQh2Z27"><s xml:id="_Agm5J4N">In essence, Δ  (,  0 ) can be interpreted as the "residual" treatment effect on the primary outcome, after we account for the treatment effect on the surrogate markers by forcing the surrogate marker distributions in the two groups to look the same.</s><s xml:id="_YkG7JCH">If the treatment effect is entirely through the surrogate markers, then we would expect Δ  (,  0 ), the residual treatment effect, to be zero.</s><s xml:id="_4CqAsyX">In contrast, if there is no treatment effect on the surrogate markers, we would expect Δ  (,  0 ) to be equal to Δ().</s></p><p xml:id="_hxUGEjY"><s xml:id="_mCe4UeF">Defining the expectation in (1) requires specifying a reference distribution for   0 .</s><s xml:id="_2SBtSN6">Without loss of generality, we choose it to be the distribution of  ()  0 , which leads to</s></p><formula xml:id="formula_2">Δ 𝐒 (𝑡, 𝑡 0 ) = 𝑃(𝑇 (𝐵) &gt; 𝑡 0 ) × ∫ 𝐬 𝜓 𝐴 (𝑡 | 𝐬, 𝑡 0 )𝑑𝐹 𝐵 (𝐬 | 𝑡 0 ) -𝑃(𝑇 (𝐵) &gt; 𝑡),</formula><p xml:id="_eJ3ezyh"><s xml:id="_ERXwxmP">where  = ( 1 , … ,   )  ,   ( |  0 ) = ( () ≤  |  () &gt;  0 ),   ( | ,  0 ) = ( () &gt;  |  () = ,  () &gt;  0 ), and throughout, we let  ≤  denote the event { 1 ≤  1 , … ,   ≤   }.</s></p><p xml:id="_bnUuesa"><s xml:id="_WdGtV4r">With Δ  (,  0 ), we define the proportion of treatment effect explained by   0 as:   (,  0 ) = {Δ() -Δ  (,  0 )}∕Δ() = 1 -Δ  (,  0 )∕Δ.</s></p><p xml:id="_sa6CTgX"><s xml:id="_tZdpQxc">These definitions are parallel to those proposed in <ref type="bibr" target="#b30">Parast et al. (2017)</ref> and <ref type="bibr" target="#b42">Wang and Taylor (2002)</ref>, expanded to the multiple marker setting.</s><s xml:id="_NVDhXNr">This framework is appealing in that it defines   (,  0 ) directly by quantifying (a) the treatment effect and (b) the piece of the treatment effect that is explained by the surrogate information.</s><s xml:id="_m24sbHy">However, the existence of multiple markers introduces significant complexities in the estimation of   (,  0 ).</s><s xml:id="_7PrQKYW">In this paper, we focus on robust estimation of this proportion using censored data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3" xml:id="_M6HKfjK">Assumptions</head><p xml:id="_KD2wMZ6"><s xml:id="_vC4XzXk">Parallel to <ref type="bibr" target="#b30">Parast et al. (2017)</ref>, a number of assumptions are required to ensure identifiability, that   (,  0 ) is between 0 and 1, and that we are not in a surrogate paradox situation in which the treatment may have a positive effect on the surrogate markers, the surrogate markers and the primary outcome may be positively associated, but the treatment has a negative effect on the primary outcome ( <ref type="bibr">Van-derWeele, 2013)</ref>.</s><s xml:id="_kxTFnCa">In addition to Assumptions (A1) and (A2), we assume:</s></p><p xml:id="_pBQUs3Y"><s xml:id="_GK7wxQd">(A3)   ( | ,  0 ) is a component-wise monotone increasing function in ; (A4) ( () &gt; ,  () &gt;  0 ) ≥ ( () &gt; ,  () &gt;  0 ) for all ; (A5)   (|,  0 ) ≥   (|,  0 ) for all .</s></p><p xml:id="_ra7ra3A"><s xml:id="_pTpmeSS">Assumptions (A1) and (A2) together can be interpreted as the surrogate information under treatment A would not affect the distribution of  under treatment B, if the surrogate information under treatment B is given (and vice versa).</s><s xml:id="_Q8KMUv5">In most settings, it is reasonable to expect these assumptions to hold, but careful consideration is needed in specific applications.</s><s xml:id="_furJbBx">Assumption (A3) implies that  at time  0 is "positively" related to the residual survival time, that is, survival to  given survival to  0 ; (A4) implies that there is a positive treatment effect on the set of surrogate markers; and (A5) requires that there is a nonnegative residual treatment effect beyond that on .</s><s xml:id="_qHd3AWY">Assumptions (A3), (A4), and (A5) ensure that   (,  0 ) is always between 0 and 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3" xml:id="_8w5Cm5Y">ESTIMATION AND INFERENCE</head><p xml:id="_YexKsFa"><s xml:id="_GeJnxFd">Due to censoring, the observed data consist of  observations {(  ,   ,   ,   (  &gt;  0 )),  = 1, … , } from the two treatment groups, where   = min(  ,   ),   = (  &lt;   ), and   denotes the censoring time for the th subject.</s><s xml:id="_9sHrhPp">We assume independent censoring, that is, (  ,   ) ⟂   |   .</s><s xml:id="_YUSQRDE">For ease of notation, we also let {(  ,   ,   (  &gt;  0 )),  = 1, … ,   } denote   = ∑  =1 (  = ) observations from treatment group  ∈ {, }, where   = min(  ,   ) and   = (  &lt;   ).</s><s xml:id="_Sg9WWTF">Without loss of generality, we assume that π =   ∕ →   ∈ (0, 1) as  → ∞.</s><s xml:id="_Gj3uTqs">Throughout, we estimate the treatment effect Δ() = ( () &gt; ) -( () &gt; ) as</s></p><formula xml:id="formula_3">Δ(𝑡) = 𝑛 -1 𝐴 𝑛 𝐴 ∑ 𝑖=1 𝐼(𝑋 𝐴𝑖 &gt; 𝑡) Ŵ𝐶 𝐴 (𝑡) -𝑛 -1 𝐵 𝑛 𝐵 ∑ 𝑖=1 𝐼(𝑋 𝐵𝑖 &gt; 𝑡) Ŵ𝐶 𝐵 (𝑡)</formula><p xml:id="_3HxAuVB"><s xml:id="_hrRWFDm">,</s></p><p xml:id="_Kcfr6zQ"><s xml:id="_sQMCZhn">where Ŵ  () is the Kaplan-Meier estimator of    () = (  &gt; ).</s><s xml:id="_6gQYeky">We propose three robust estimators for Δ  (,  0 ): (I) a two-stage smoothing-based estimator, (II) a double robust estimator obtained by incorporating weighting into the first estimator to guard against misspecification of the working model used in (I), and (III) a second double robust estimator incorporating weights in an alternative way.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1" xml:id="_Fw5gYF4">Two-stage estimator</head><p xml:id="_bxnDxvv"><s xml:id="_D5QaveY">First, we propose a two-stage procedure combining the use of a working model and a nonparametric estimation procedure for Δ  (,  0 ), building upon the multiple marker estimation procedure given in <ref type="bibr" target="#b31">Parast et al. (2015)</ref> for the uncensored setting and <ref type="bibr" target="#b30">Parast et al. (2017)</ref>, which handled censored data with a single marker.</s><s xml:id="_rrvEfq7">The idea is simply to summarize  into a univariate score  and then construct a nonparametric estimator for   (,  0 ) treating  as .</s><s xml:id="_DBn8CpF">To construct , we approximate the conditional distribution of  () |  () ,  () &gt;  0 by using a working semiparametric model such as the landmark proportional hazards model (Van Houwelingen and Putter, 2012):</s></p><formula xml:id="formula_4">𝑞 𝐴 (𝐒) = 𝑃(𝑇 (𝐴) &gt; 𝑡 | 𝑇 (𝐴) &gt; 𝑡 0 , 𝐒 (𝐴) ) = exp{-Λ 0 (𝑡|𝑡 0 ) exp(𝜷 𝖳 𝐒 (𝐴) )}, 𝑡 &gt; 𝑡 0 ,<label>(2)</label></formula><p xml:id="_j2Rys6p"><s xml:id="_7enPUws">where Λ 0 (| 0 ) is the unspecified baseline cumulative hazard function for  () conditional on { () &gt;  0 } and  is an unknown vector of coefficients.</s><s xml:id="_payWXNJ">Let β be the maximizer of the corresponding log partial likelihood function and Λ0 (| 0 ) be the Breslow-type estimate of baseline hazard <ref type="bibr" target="#b10">(Breslow, 1972)</ref>.</s><s xml:id="_74Sfx4W">If one were to assume that ( <ref type="formula" target="#formula_4">2</ref>) is correctly specified, then a consistent estimate of Δ  (,  0 ) would simply be:</s></p><formula xml:id="formula_5">Δ𝑀 𝐒 = 𝑛 -1 𝐵 𝑛 𝐵 ∑ 𝑖=1 [ exp {-Λ0 (𝑡|𝑡 0 ) exp( β𝖳 𝐒 𝐵𝑖 )} 𝐼(𝑋 𝐵𝑖 &gt; 𝑡 0 ) Ŵ𝐶 𝐵 (𝑡 0 ) - 𝐼(𝑋 𝐵𝑖 &gt; 𝑡) Ŵ𝐶 𝐵 (𝑡) ] .<label>(3)</label></formula><p xml:id="_tEGqgF3"><s xml:id="_F4gFmzP">However, if (2) is not correctly specified, Δ  (,  0 ) may be a biased estimate of Δ  (,  0 ) <ref type="bibr" target="#b29">(O'neill, 1986;</ref><ref type="bibr" target="#b23">Lagakos, 1988)</ref>.</s><s xml:id="_zmKRNmU">On the other hand, even when (2) is misspecified, β converges to a deterministic limit  0 in probability as   → ∞ under general regularity conditions <ref type="bibr" target="#b21">(Hjort, 1992)</ref>.</s><s xml:id="_hnkMdqx">Therefore, we may use the resulting score  =   0  as a univariate "pseudo-marker" to summarize the  surrogates.</s></p><p xml:id="_z245vHR"><s xml:id="_kb3E7e2">In the second stage, to estimate Δ  (,  0 ), we apply the nonparametric approach proposed in <ref type="bibr" target="#b30">Parast et al. (2017)</ref> with  represented by the univariate marker .</s><s xml:id="_Y6Dww3Y">Specifically, we use a kernel Nelson-Aalen estimator to nonparametrically estimate   (|,  0 ) = ( ()</s></p><formula xml:id="formula_6">&gt; 𝑡 | 𝑈 (𝐴) = 𝑢, 𝑇 (𝐴) &gt; 𝑡 0 ) = exp{-Λ 𝐴 (𝑡|𝑢, 𝑡 0 )} as φ𝐴 (𝑡|𝑢, 𝑡 0 ) = exp{-Λ𝐴 (𝑡|𝑢, 𝑡 0 )}, where Λ𝐴 (𝑡|𝑢, 𝑡 0 ) = ∫ 𝑡 𝑡 0 ∑ 𝑛 𝐴 𝑖=1 𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑑𝑁 𝐴𝑖 (𝑧) ∑ 𝑛 𝐴 𝑖=1 𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑌 𝐴𝑖 (𝑧) ,<label>(4)</label></formula><p xml:id="_wW6KugY"><s xml:id="_SU2KM3M">Û = β   , Û = β   ,   = (  ≥ ),   () = (  ≤ )  , (⋅) is a smooth symmetric density function,  ℎ () = (∕ℎ)∕ℎ, and (⋅) is a given monotone transformation function, similar to the approach used in <ref type="bibr" target="#b32">Parast et al. (2014)</ref> in a different context.</s><s xml:id="_AQgZEhs">We let the bandwidth ℎ =   ( -  ) with  ∈ (1∕4, 1∕2) to impose undersmoothing to eliminate the asymptotic impact of the bias of Λ (|,  0 ) on the resulting estimator.</s><s xml:id="_tY3vsDg">We then estimate Δ  (,  0 ) as</s></p><formula xml:id="formula_7">Δ𝐒 (𝑡, 𝑡 0 ) = 𝑛 -1 𝐵 𝑛 𝐵 ∑ 𝑖=1 [ φ𝐴 ( 𝑡| Û𝐵𝑖 , 𝑡 0 ) 𝐼(𝑋 𝐵𝑖 &gt; 𝑡 0 ) Ŵ𝐶 𝐵 (𝑡 0 ) - 𝐼(𝑋 𝐵𝑖 &gt; 𝑡) Ŵ𝐶 𝐵 (𝑡)</formula><p xml:id="_C2mC9qp"><s xml:id="_vKJasyE">] and R (,  0 ) = 1 -Δ (,  0 )∕ Δ().</s></p><p xml:id="_Tyx7cna"><s xml:id="_8D7RCCP">In Web Appendix A, we show that when (2) holds, Δ (,  0 ) and R (,  0 ) are respective consistent estimators of Δ  (,  0 ) and   (,  0 ), √ { Δ (,  0 ) -Δ  (,  0 )} → (0,  2 1 ), and √ { R (,  0 ) -  (,  0 )} → (0,  2 2 ), with  2 1 and  2 2 defined in Web Appendix A. In addition, we show that regardless of the adequacy of (2), Δ (,  0 ) and R (,  0 ) always consistently estimate Δ  (,  0 ) and   (,  0 ) = 1 -Δ  (,  0 )∕Δ(), respectively, where</s></p><formula xml:id="formula_8">Δ 𝑈 (𝑡, 𝑡 0 ) = 𝑃(𝑇 (𝐵) &gt; 𝑡 0 ) ∫ 𝜙 𝐴 (𝑡 | 𝑢, 𝑡 0 )𝑑𝐹 𝐵 (𝑢 | 𝑡 0 ) -𝑃(𝑇 (𝐵) &gt; 𝑡),</formula><p xml:id="_4ezGwKu"><s xml:id="_mNU3vfW">and   ( |  0 ) = ( () ≤  |  () &gt;  0 ).</s><s xml:id="_aXghYFX">This property is expected given the asymptotic results presented in <ref type="bibr" target="#b30">Parast et al. (2017)</ref> for the single marker setting; that is, once we transform multiple surrogate markers to a single psuedomarker , the properties of the corresponding estimate would hold with respect to that .</s><s xml:id="_8YgPbQv">Lastly, it can be shown that if</s></p><formula xml:id="formula_9">𝐼(𝑇 (𝐴) ≥ 𝑡) ⟂ 𝐒 (𝐴) | 𝑈 (𝐴) , 𝑇 (𝐴) ≥ 𝑡 0 ,<label>(5)</label></formula><p xml:id="_5C5DAxy"><s xml:id="_KZwrvf5">then Δ  (,  0 ) = Δ  (,  0 ) and thus, R (,  0 ) would be a consistent estimator of   (,  0 ).</s><s xml:id="_nytyF44">Note that (5) implies that even if the regression model is misspecified, it is still possible that  captures all of the association between  and  for our specific purpose.</s><s xml:id="_tbe2FBY">In general, using  as a way to summarize the multiple surrogates should perform better than an arbitrary combination of the surrogates; we illustrate this further in Section 4.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2" xml:id="_awTWYqC">Two-stage weighted estimator</head><p xml:id="_eF7pksJ"><s xml:id="_adu52c6">While the estimator R is constructed to estimate the full surrogacy of , it may not approximate this well if the working model (2) fails to characterize the distribution of  given , for example, if model ( <ref type="formula" target="#formula_4">2</ref>) is incorrectly specified.</s><s xml:id="_ZsMRY4U">In that case, the estimator Δ (,  0 ) may correctly capture the residual treatment effect at  0 when the composite marker  () within the two groups were the same, but not necessarily the residual treatment effect if  within these two groups was the same, which is the goal.</s><s xml:id="_gnF7za6">To derive a more robust estimator, we borrow ideas from the extensive causal inference literature focusing on double robust estimators <ref type="bibr" target="#b27">(Lunceford and Davidian, 2004;</ref><ref type="bibr" target="#b8">Bang and Robins, 2005;</ref><ref type="bibr" target="#b20">Glynn and Quinn, 2010;</ref><ref type="bibr" target="#b24">Lee et al., 2010;</ref><ref type="bibr" target="#b36">Rotnitzky et al., 2012)</ref>.</s><s xml:id="_ahag2VE">Specifically, we propose a two-stage weighted estimator with a propensity score weight explicitly balancing the two treatment groups with respect to the distribution of .</s><s xml:id="_5ZJ2q6U">The weighting enables us to "adjust" the distribution of  () before constructing the conditional survival estimate φ (|,  0 ).</s><s xml:id="_aWbHsh3">As demonstrated below, this approach results in a double-robust estimator of Δ  (,  0 ), which is consistent when either  () captures all the information about the relationship between ( () ≥ ) and  () or the propensity score model for (,  0 ) = (  = |  = ,   &gt;  0 ) is correctly specified.</s><s xml:id="_4Ck7RBM">While (,  0 ) depends on  0 , for simplicity, we drop  0 from our notation and simply use ().</s></p><p xml:id="_RWNWUHF"><s xml:id="_9QmRae4">Regression models can be imposed to obtain estimates for ().</s><s xml:id="_DxDS2eF">For example, a simple logistic regression model can be imposed for π() = (  = |  = ,   &gt;  0 ) with logit{ π()} =  0 +   1 ,</s></p><p xml:id="_9MZ82Fz"><s xml:id="_5924WjB">where  0 and  1 are estimated only among those with   &gt;  0 to account for censoring.</s><s xml:id="_CTCfPyw">The propensity score of interest, (), can be derived from π() directly since</s></p><formula xml:id="formula_11">logit{𝜋(𝐬)} = logit{ π(𝐬)} + log { 𝑊 𝐶 𝐴 (𝑡 0 )∕𝑊 𝐶 𝐵 (𝑡 0 ) } ,</formula><p xml:id="_sjUkU9W"><s xml:id="_9aQG5XT">which follows from the assumption that (  ,   ) ⟂   .</s></p><p xml:id="_qd2Afpf"><s xml:id="_SZT3Pdj">We then modify (4) by weighting observations with the estimated (  ) = (  )∕{1 -(  )} and obtain</s></p><formula xml:id="formula_12">Λ𝑤 𝐴 (𝑡|𝑢, 𝑡 0 ) = ∫ 𝑡 𝑡 0 ∑𝑛 𝐴 𝑖=1 L(𝐒 𝐴𝑖 )𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑑𝑁 𝐴𝑖 (𝑧) ∑𝑛 𝐴 𝑖=1 L(𝐒 𝐴𝑖 )𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑌 𝐴𝑖 (𝑧) = ∫ 𝑡 𝑡 0 ∑𝑛 𝐴 𝑖=1 exp ( α𝖳 1 𝐒 𝐴𝑖 ) 𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑑𝑁 𝐴𝑖 (𝑧) ∑𝑛 𝐴 𝑖=1 exp ( α𝖳 1 𝐒 𝐴𝑖 ) 𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 )𝐾 ℎ {𝛾( Û𝐴𝑖 ) -𝛾(𝑢)}𝑌 𝐴𝑖 (𝑧) ,<label>(7)</label></formula><p xml:id="_pPMuApb"><s xml:id="_XvJ6aA7">where L(  ) = exp(α 0 + α 1   ) Ŵ  ( 0 )∕ Ŵ  ( 0 ).</s><s xml:id="_k8X78dY">Subsequently, we define</s></p><formula xml:id="formula_13">Δ𝑤 𝐒 (𝑡, 𝑡 0 ) = 𝑛 -1 𝐵 𝑛 𝐵 ∑ 𝑖=1 [ φ𝑤 𝐴 (𝑡| Û𝐵𝑖 , 𝑡 0 ) 𝐼(𝑋 𝐵𝑖 &gt; 𝑡 0 ) Ŵ𝐶 𝐵 (𝑡 0 ) - 𝐼(𝑋 𝐵𝑖 &gt; 𝑡) Ŵ𝐶 𝐵 (𝑡) ]<label>(8)</label></formula><p xml:id="_H4B6nyV"><s xml:id="_ScaCqdQ">and R  (,  0 ) = 1 -Δ  (,  0 )∕ Δ(), where φ  (| 0 , ) = exp{-Λ  (| 0 , )}.</s><s xml:id="_qEkV6aP">Intuitively, we consider our pseudo-marker  as a potentially flawed attempt to capture all information in  (through dimension reduction).</s><s xml:id="_q7cHnX5">The analogous situation in an observational study is a treatment effect estimator based on a regression model conditional on  that is biased due to a residual confounding effect from .</s><s xml:id="_kgdn4zt">In such a case, it is advantageous to use propensity score weighting to additionally balance .</s><s xml:id="_Z36Qxk6">Our setting is certainly more complicated, since  is measured postbaseline, but the concept is similar.</s><s xml:id="_NnX2rDD">The need for weighting comes from the fact that "balancing" with respect to  may not be sufficient when  does not fully capture the information of .</s><s xml:id="_VJQtXyV">When  is flawed, the weighting proposed here offers us a second chance to recover consistency.</s></p><p xml:id="_jNtnBjz"><s xml:id="_qyqCyqR">In Web Appendix B, we show that when either (a) model ( <ref type="formula" target="#formula_10">6</ref>) is correctly specified, or (b) ( () ≥ ) ⟂  () |  () ,  () ≥  0 , our proposed estimate Δ  (,  0 ) is a consistent estimate of Δ  (,  0 ).</s><s xml:id="_xqEtcDa">Specifically, we demonstrate that when the propensity score model ( <ref type="formula" target="#formula_10">6</ref>) is correctly specified,</s></p><formula xml:id="formula_14">𝑛 -1 𝐵 𝑛 𝐵 ∑ 𝑖=1 φ𝑤 𝐴 (𝑡| Û𝐵𝑖 , 𝑡 0 ) 𝐼(𝑋 𝐵𝑖 ≥ 𝑡 0 ) Ŵ𝐶 𝐵 (𝑡 0 ) (9) consistently estimates ∫ ∞ -∞ [ 𝑑 𝑑𝑢 ∫ 𝜷 𝖳 0 𝐬≤𝑢 𝜓 𝐴 (𝑡 | 𝐬, 𝑡 0 )𝑑𝐅 𝐵 (𝐬 | 𝑡 0 ) ] 𝑑𝑢 × 𝑃(𝑇 (𝐵) &gt; 𝑡 0 ) = 𝑃(𝑇 (𝐵) &gt; 𝑡 0 ) ∫ 𝜓 𝐴 (𝑡 | 𝐬, 𝑡 0 )𝑑𝐅 𝐵 (𝐬 | 𝑡 0 ).</formula><p xml:id="_m7VeKSE"><s xml:id="_5zsRYFA">On the other hand, if ( () ≥ ) ⟂  () | ( () , </s></p><p xml:id="_cm9hzgY"><s xml:id="_AW7f9Zf">() &gt;  0 ), then   ( | ,  0 ) =   ( |   0  = ,  0 ), whose consistent estimator is φ  ( | ,  0 ) even when the propensity score model is misspecified.</s><s xml:id="_ufxBMgb">Consequently, if either of these two scenarios is true, R  (,  0 ) is a consistent estimate of   (,  0 ), √ { Δ  (,  0 ) -Δ  (,  0 )} → (0,  2 3 ), and √ { R  (,  0 ) -  (,  0 )} → (0,  2 4 ), with  2 3 and  2 4 defined in Web Appendix B.</s></p><p xml:id="_aRFFte5"><s xml:id="_ZeDguFa">Remark 1.</s><s xml:id="_yYWBPh7">While the two-stage weighted estimator reflects one way to enhance the robustness of an initial estimator, the idea of combining a propensity-score type model and a regression-type model has certainly been extensively studied in the causal inference literature and a more familiar double-robust estimator can be constructed as:</s></p><formula xml:id="formula_15">Δ𝐷𝑅 𝐒 (𝑡, 𝑡 0 ) = 𝑛 -1 [ 𝑛 𝐴 ∑ 𝑖=1 𝐼(𝑋 𝐴𝑖 &gt; 𝑡) Ŵ𝐶 𝐴 (𝑡) π𝐵 L(𝐒 𝐴𝑖 ) - 𝑛 𝐵 ∑ 𝑖=1 𝐼(𝑋 𝐵𝑖 &gt; 𝑡) Ŵ𝐶 𝐵 (𝑡) π𝐵 ] -𝑛 -1 [ 𝑛 𝐴 ∑ 𝑖=1 φ𝐴 (𝑡 | Û𝐴𝑖 , 𝑡 0 )𝐼(𝑋 𝐴𝑖 &gt; 𝑡 0 ) Ŵ𝐶 𝐴 (𝑡 0 ) π𝐵 L(𝐒 𝐴𝑖 ) - 𝑛 𝐵 ∑ 𝑖=1 φ𝐴 (𝑡 | Û𝐵𝑖 , 𝑡 0 )𝐼(𝑋 𝐵𝑖 &gt; 𝑡 0 ) Ŵ𝐶 𝐵 (𝑡 0 ) π𝐵 ]</formula><p xml:id="_f4wx44P"><s xml:id="_UAZncJA">and R  (,  0 ) = 1 -Δ  (,  0 )∕ Δ(), where φ (| Û ,  0 ) is the (unweighted) estimate of   ( | ,  0 ) used in Δ (,  0 ).</s><s xml:id="_zkCZYpN">In Web Appendix C, we show that if either the model for () or model ( <ref type="formula" target="#formula_4">2</ref>) is correctly specified, Δ  (,  0 ) and R  (,  0 ) are consistent estimators of Δ  (,  0 ) and    (,  0 ), respectively.</s><s xml:id="_YApeUAK">Furthermore, √ { Δ  (,  0 ) -Δ  (,  0 )} → (0,  2 5 ) and √ { R  (,  0 ) -  (,  0 )} → (0,  2 6 ) as  → ∞, with  2 5 and  2 6 defined in Web Appendix C.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3" xml:id="_2fg54cM">Variance estimation</head><p xml:id="_5XXtQch"><s xml:id="_h3J4bk5">Construction of confidence intervals (CIs) for these metrics is particularly important as the 95% CI for   (,  0 ) is often used to make a decision regarding the quality of the surrogate information.</s><s xml:id="_JrDvvpY">For example, <ref type="bibr" target="#b26">Lin et al. (1997)</ref> suggest making a decision, whereby a surrogate marker is deemed promising if the lower bound of the 95% CI for this proportion is greater than 0.50.</s><s xml:id="_j9sFHqf">The variances of the proposed estimators have complex forms as shown in the Web Appendices.</s><s xml:id="_AfPdj9T">Instead of explicitly estimating these variances, we propose a perturbation-resampling method for variance and interval estimation as detailed in Web Appendix D. Briefly, perturbation-resampling is similar to standard bootstrapping in that a weight for each observation is repeatedly generated at random and used to create weighted or "perturbed" version of the estimate except that in perturbation-resampling, the weights come from a continuous distribution with unit mean and unit variance as opposed to a discrete multinomial distribution used for bootstrapping.</s><s xml:id="_BGQTcyA">The finite sample performance of the resulting variance estimates and CIs are examined in the simulation study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4" xml:id="_gBdxGcu">SIMULATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1" xml:id="_PxR8vfX">Simulation setup</head><p xml:id="_rETrASS"><s xml:id="_9JADPPF">We conducted simulation studies under three different settings to assess the performance of the proposed estimators.</s><s xml:id="_kEXTj8S">In setting 1, we generated data such that the landmark model ( <ref type="formula" target="#formula_4">2</ref>) is correctly specified, but model ( <ref type="formula" target="#formula_10">6</ref>) is not correctly specified.</s><s xml:id="_HNEzabb">Specifically,   =   = 1000, where   =  for  = 1, … ,   and   =  for  = 1, … ,   and within each group, data were generated as follows:</s></p><formula xml:id="formula_16">𝐒 𝐴 ∼ 𝑁 ⎡ ⎢ ⎢ ⎢ ⎢ ⎣ ⎛ ⎜ ⎜ ⎜ ⎜ ⎝ 0.161 0.345 0.322 0.69 ⎞ ⎟ ⎟ ⎟ ⎟ ⎠ , ⎛ ⎜ ⎜ ⎜ ⎜ ⎝ 4 2 1 2 2 5 3 2 1 3 6 3 2 2 3 7 ⎞ ⎟ ⎟ ⎟ ⎟ ⎠ ∕50 ⎤ ⎥ ⎥ ⎥ ⎥ ⎦ , 𝐒 𝐵 ∼ 𝑁 ⎡ ⎢ ⎢ ⎢ ⎢ ⎣ ⎛ ⎜ ⎜ ⎜ ⎜ ⎝</formula><p xml:id="_vvcQJuh"><s xml:id="_rVUU2SR">0.12 0.24 0.22 0.48</s></p><formula xml:id="formula_17">⎞ ⎟ ⎟ ⎟ ⎟ ⎠ , ⎛ ⎜ ⎜ ⎜ ⎜ ⎝ 4 2 1 2 2 5 3 2 1 3 6 3 2 2 3 7 ⎞ ⎟ ⎟ ⎟ ⎟ ⎠ ∕80 ⎤ ⎥ ⎥ ⎥ ⎥ ⎦</formula><p xml:id="_meevA6J"><s xml:id="_4wxxmyJ">,   = -log(1 -  )∕ exp{-     + 0.2}, and   = -log (1 -  )∕ exp{-     + 0.1}, where   ∼ (0, 1),   ∼ (0, 1),   = (1.2,</s><s xml:id="_2BKY7sK">1.7, 2.2, 2.7)  ,   = (0.5, 1.0, 1.5, 2)  , censoring in both groups is generated from (0, 3), and (,  0 ) = (1, 0.5).</s><s xml:id="_hgfj2VA">In this setting, Δ() = 0.16, Δ  (,  0 ) = 0.04, and   (,  0 ) = 0.74.</s><s xml:id="_Rt9U4Sd">In setting 2, we generated data such that model ( <ref type="formula" target="#formula_10">6</ref>) is correctly specified, but model ( <ref type="formula" target="#formula_4">2</ref>) is misspecified.</s><s xml:id="_kVu9q42">Specifically,</s></p><formula xml:id="formula_18">( 𝐒 log 𝑇 * ) ∼ 𝑁 ⎡ ⎢ ⎢ ⎢ ⎢ ⎢ ⎣ ⎛ ⎜ ⎜ ⎜ ⎜ ⎜ ⎝</formula><p xml:id="_AFHQGfM"><s xml:id="_mUkdx65">0.12 0.24 0.22 0.48 -0.2</s></p><formula xml:id="formula_19">⎞ ⎟ ⎟ ⎟ ⎟ ⎟ ⎠ , ⎛ ⎜ ⎜ ⎜ ⎜ ⎜ ⎝ 4 2 1 2 3 2 5 3 2 3 1 3 6 3 3 2 2 3 7 4 3 3 3 4 10 ⎞ ⎟ ⎟ ⎟ ⎟ ⎟ ⎠ ∕50 ⎤ ⎥ ⎥ ⎥ ⎥ ⎥ ⎦</formula><p xml:id="_hPeGWwa"><s xml:id="_2Y8whkD">, and  = {( = 1)} + {( = 0)}, where  ∼  (),  = {1 + exp(-   )} -1 ,   = (-0.6,</s><s xml:id="_XCGSTsD">-0.4,</s><s xml:id="_95sVGhD">-0.3, -0.2)  , and   =  *  + 0.09 × (  = ,  *  &gt;  0 ).</s><s xml:id="_ttmRZ3e">That is,   =   for observations with   =  and   =   for observations with   = , and the total sample size   +   = 2000.</s><s xml:id="_xty8XTR">Censoring in both groups is generated from (0, 3), and (,  0 ) = (1, 0.5).</s><s xml:id="_Rm88E3g">In this setting, Δ() = 0.15, Δ  (,  0 ) = 0.08, and   (,  0 ) = 0.51.</s><s xml:id="_qgP3M9d">In setting 3, we generated data with   =   = 1000 such that both model ( <ref type="formula" target="#formula_10">6</ref>) and model ( <ref type="formula" target="#formula_4">2</ref>) do not hold.</s><s xml:id="_nHBuJAk">Specifically, within each group, data were generated as:</s></p><formula xml:id="formula_20">𝐒 𝐴 ∼ ⎛ ⎜ ⎜ ⎜ ⎜ ⎝ Gamma(2, 2) exp{Normal(0.1, 0.2 2 )} Bernoulli(0.2) ⎞ ⎟ ⎟ ⎟ ⎟ ⎠ , 𝐒 𝐵 ∼ ⎛ ⎜ ⎜ ⎜ ⎜ ⎝ Gamma(7, 0.5) exp{Normal(0, 0.1 2 )} Bernoulli(0.1) ⎞ ⎟ ⎟ ⎟ ⎟ ⎠</formula><p xml:id="_jbVY6w5"><s xml:id="_pv5qRtx">and   = 0.1 + 0.005 2 1  2 + 0.03 1  2  3 + 0.25 × exp(0.005</s><s xml:id="_w9qqHut">1  3 ) + exp( 1 ) and   = 0.002 2 1  2 + 0.025 1  2  3 + 0.25 × exp(0.003</s><s xml:id="_kTRNgTV">1  3 ) + exp( 2 ), where   = ( 1 ,  2 ,  3 )  ,   = ( 1 ,  2 ,  3 )  ,  1 ∼ Normal(-0.5,</s><s xml:id="_K8RjVbh">1),  2 ∼ Normal(-0.5,</s><s xml:id="_2RckdVt">1), censoring in both groups is generated from (0, 3), and (,  0 ) = (1, 0.5).</s><s xml:id="_mM8G8vH">In this setting, Δ() = 0.15, Δ  (,  0 ) = 0.03, and   (,  0 ) = 0.81.</s></p><p xml:id="_CFa6myR"><s xml:id="_VeK5XDx">For all settings, we let the bandwidth ℎ = ℎ   -0.11  =   ( -0.31 ) to ensure the desired theoretical rate for ℎ,</s></p><formula xml:id="formula_21">where ℎ 𝑜𝑝𝑡 = 𝑂 𝑝 (𝑛 -1∕5 𝐴</formula><p xml:id="_P3R725y"><s xml:id="_2Tt7MEH">) is obtained via the optimal bandwidth selection procedure given by <ref type="bibr" target="#b37">Scott (1992)</ref>.</s><s xml:id="_mJHJaBH">Throughout, a simple logistic regression model is used, as described in Section 3.2, for ().</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2" xml:id="_HpGtfSH">Model-based estimators for comparison</head><p xml:id="_2937yXY"><s xml:id="_2g8ghgp">In order to compare the performance of our proposed robust estimators to model-based estimators in these different settings, we define three additional model-based estimators.</s><s xml:id="_GrpCh3b">Importantly, the following three model-based estimators do not exist in the literature and are themselves novel in this setting.</s><s xml:id="_te5sRNd">Our aim in introducing these estimators for comparison is to demonstrate the value of the robustness of our proposed estimators, as well as the trade-offs made when certain specified models are indeed correctly specified.</s><s xml:id="_nmJujKn">We define Δ  (,  0 ) as the estimator given in (3), which relies completely on the correct specification of (2), and R  (,  0 ) = 1 -Δ  (,  0 )∕ Δ().</s><s xml:id="_XR75X8K">Second, we define a propensity-score weighted estimator</s></p><formula xml:id="formula_22">Δ𝑃𝑆 𝐒 (𝑡, 𝑡 0 ) = 𝑛 -1 𝑛 ∑ 𝑖=1 { 𝐼(𝑋 𝑖 &gt; 𝑡) Ŵ𝐶 𝐺 𝑖 (𝑡) π𝐵 [ 𝐼(𝐺 𝑖 = 𝐴) L(𝐒 𝐴𝑖 ) -𝐼(𝐺 𝑖 = 𝐵) ] }</formula><p xml:id="_wXRCg9v"><s xml:id="_wu4u3gT">and R  (,  0 ) = 1 -Δ  (,  0 )∕ Δ().</s><s xml:id="_EDkqZYx">This estimator completely relies on the correct specification of ().</s><s xml:id="_YpppKeG">Lastly, we define a model-based double-robust estimator Δ2  (,  0 ) and R2  (,  0 ) = 1 -Δ2  (,  0 )∕ Δ() constructed parallel to the construction of Δ  (,  0 ), that is, a combination of Δ  (,  0 ) and R  (,  0 ).</s><s xml:id="_sv2Z4M3">Similar to our double-robust estimators, this estimator would be consistent if either (2) or (6) were correctly specified, but would not have the property that our double-robust estimators have whereby it still consistently estimates   (,  0 ) even when both models are misspecified.</s><s xml:id="_XeFdWXV">Notably, none of these model-based estimators incorporate a smoothing component.</s><s xml:id="_kzQbrAx">The aforementioned model-based estimators are expected to perform well when the model specified by that approach holds, but perform poorly in setting 3 where neither model holds.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3" xml:id="_qB9vFUe">Simulation goals</head><p xml:id="_9vQZPc9"><s xml:id="_UVgUkpt">The goals of the simulation study are to show that (a) when model ( <ref type="formula" target="#formula_4">2</ref>) is correctly specified, regardless of correct specification for model ( <ref type="formula" target="#formula_10">6</ref>), all proposed estimators perform well in terms of minimal bias, standard error estimates are close to the empirical standard error estimates and coverage is close to the nominal level of 0.95; (b) when model ( <ref type="formula" target="#formula_10">6</ref>) is correctly specified, regardless of correct specification for model (2), both proposed double-robust estimators perform well; and (c) when neither model (2) nor model ( <ref type="formula" target="#formula_10">6</ref>) is correctly specified, we would still expect reasonable performance for our proposed estimators unless  dramatically fails to characterize the information contained in .</s></p><p xml:id="_2Uc667u"><s xml:id="_SW4XE8y">ESE 0.023 0.023 0.023 0.023 0.023 0.023 ASE 0.022 0.022 0.022 0.022 0.022 0.022 MSE 0.001 0.001 0.001 0.001 0.001 0.001 Coverage 0.923 0.925 0.939 0.930 0.935 0.938 Setting 3 Proposed Model-based Δ (,   ) Δ  (,   ) Δ  (,   ) Δ  (,   ) Δ  (,   ) Δ  (,   ) Bias 0.004 0.003 -0.001 0.026 0.065 0.019 ESE 0.027 0.030 0.031 0.025 0.034 0.030 ASE 0.027 0.029 0.032 0.025 0.033 0.030 MSE 0.001 0.001 0.001 0.001 0.005 0.001 Coverage 0.949 0.948 0.960 0.794 0.491 0.897 Note.</s><s xml:id="_Mtt7ay9">Proposed estimators are compared with fully model-based estimates: Δ  (,  0 ), Δ  (,  0 ), and Δ2  (,  0 ).</s><s xml:id="_vKsMNkP">Abbreviations: ASE, average standard error; ESE, empirical standard error; MSE, mean squared error; Coverage, coverage of 95% confidence intervals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4" xml:id="_Pum3AvQ">Simulation results</head><p xml:id="_jNWGUGq"><s xml:id="_skXmATy">Tables <ref type="table">1</ref> and <ref type="table">2</ref> show the results of estimating Δ  (,  0 ) and   (,  0 ), respectively, under each setting across 1000 simulations.</s><s xml:id="_R7dffff">Overall these results show that all three proposed estimators generally have minimal bias, estimated standard error estimates close to the empirical standard errors, and coverage close to the nominal level of 0.95.</s><s xml:id="_8hTcKwb">Specifically examining estimation of   (,  0 ) (Table <ref type="table">2</ref>), in setting 1 where model ( <ref type="formula" target="#formula_4">2</ref>) is correctly specified, all proposed estimators perform reasonably well and similarly in terms of bias (goal (a) above).</s><s xml:id="_SCgXEtb">Comparing to the model-based estimator    (,  0 ), also shown in Table <ref type="table">2</ref>, this estimator has smaller bias in setting 1 since the model that it relies on is, in fact, correct here.</s><s xml:id="_FYrrQxn">That is, we see that we pay a small price in terms of minimal bias by using the two-stage estimator, which smooths over the pseudo-score  when such smoothing is unnecessary.</s><s xml:id="_z79dRNa">As expected, the model-based propensity score estimator,    (,  0 ), included for comparison, has larger bias since the model for () is not correctly specified.</s></p><p xml:id="_unfsv53"><s xml:id="_rZ8N8ZY">Under setting 2 where the model for () is correctly specified, both estimators that incorporate propensity score weighting have minimal bias while the twostage estimator, which does not incorporate weighting, has slightly larger bias (goal (b) above).</s><s xml:id="_KzDHHdU">We see very minimal bias for the weighted model-based estimator and the model-based double-robust estimator, which is expected since they are valid under correct specification of ().</s></p><p xml:id="_cqkr4sZ"><s xml:id="_fjAsjwJ">Lastly, in setting 3 when neither model is correct, all three proposed estimators perform reasonably well (goal (c) above).</s><s xml:id="_nresAzp">This can be compared to the model-based estimators, which have substantial bias for all three modelbased comparison estimators.</s><s xml:id="_W4ZwqNe">These results highlight the robustness of the three proposed estimators to potential model misspecification.</s></p><p xml:id="_48a47KA"><s xml:id="_SweCfje">In Web Appendix E, we present additional simulation results for all settings examining two additional estimators similar to R (,  0 ) except that they are based on arbitrary combinations of  as opposed to  = β .</s><s xml:id="_CH8zczS">In Web Appendix E, we also present an additional simulation setting generated such that the surrogate is time-varying and TA B L E 2 Performance of the proposed estimators of   (,  0 ) under setting 1, when the conditional survival model is correctly specified, setting 2, when the model for () is correctly specified, and setting 3 when neither model is correctly specified</s></p><p xml:id="_xCcuvB7"><s xml:id="_e85cAz4">Setting 1 Proposed Model-based R (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) Bias -0.021 -0.013 0.012 0.002 -0.042 0.001 ESE 0.080 0.083 0.110 0.080 0.125 0.110 ASE 0.083 0.085 0.118 0.086 0.136 0.118 MSE 0.007 0.007 0.012 0.006 0.018 0.012 Coverage 0.922 0.927 0.958 0.950 0.944 0.960 Setting 2 Proposed Model-based R (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) Bias -0.031 -0.024 0.006 0.015 0.006 0.006 ESE 0.090 0.091 0.094 0.093 0.093 0.093 ASE 0.095 0.096 0.104 0.101 0.102 0.102 MSE 0.009 0.009 0.009 0.009 0.009 0.009 Coverage 0.897 0.908 0.949 0.941 0.945 0.947 Setting 3 Proposed Model-based R (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) R  (,   ) Bias -0.003 0.002 0.027 -0.158 -0.422 -0.106 ESE 0.158 0.185 0.200 0.120 0.175 0.175 ASE 0.193 0.215 0.240 0.149 0.196 0.206 MSE 0.025 0.034 0.041 0.039 0.209 0.042 Coverage 0.945 0.951 0.963 0.732 0.396 0.881 Note.</s><s xml:id="_kQ2Ej9e">Proposed estimators are compared with fully model-based estimates: R  (,  0 ), R  (,  0 ), and R2  (,  0 ).</s><s xml:id="_nvpZaZq">Abbreviations: ASE, average standard error; ESE, empirical standard error; MSE, mean squared error; Coverage, coverage of 95% confidence intervals.</s></p><p xml:id="_N5CrGJc"><s xml:id="_hdTScZq">use our methods to examine the proportion of the treatment effect explained at two different time points.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5" xml:id="_QkW7W5N">EXAMPLE</head><p xml:id="_FusGKW6"><s xml:id="_3JFgBPM">We use the proposed estimators to examine multiple surrogate markers in a diabetes clinical trial setting.</s><s xml:id="_vWps678">This is of particular interest given that the development of methods to validate surrogate markers to allow for an early assessment of treatment adequacy was identified as a critical challenge in the Strategic Planning Report of the Diabetes Mellitus Interagency Coordinating Committee of the National Institute of Diabetes and Digestive and Kidney Diseases <ref type="bibr">(NIDDK, 2011)</ref>.</s><s xml:id="_5yknZRg">Specifically, we use data from the DPP Study, a randomized study designed to investigate the efficacy of various treatments on the development of diabetes in high-risk adults <ref type="bibr" target="#b15">(DPPG, 1999</ref><ref type="bibr" target="#b16">(DPPG, , 2002))</ref>.</s><s xml:id="_ad8PU3F">DPP data are publicly available through the the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository <ref type="bibr" target="#b14">(DPP, 2013)</ref>.</s><s xml:id="_ruVAbPe">Participants were randomly assigned to either a placebo group or one of three treat-ment groups: metformin, troglitazone, or lifestyle intervention.</s><s xml:id="_n9u9zuc">The primary endpoint was time to diabetes as defined by the protocol at the time of the visit: fasting glucose ≥140 mg/dL (for visits through 6/23/1997, ≥126 mg/dL for visits on or after 6/24/2007) or 2-hour postchallenge glucose ≥200 mg/dL.</s><s xml:id="_T8U5kmb">We focus on the comparison between the placebo group (  = 1030) and the lifestyle intervention group (  = 1023).</s><s xml:id="_MnZwXGH">We let  = 3 years and  0 = 1 year.</s><s xml:id="_nwsPyab">Figure <ref type="figure">1a</ref> shows the diabetes-free survival probability over time for each group.</s><s xml:id="_v93NACB">The estimated treatment effect, Δ(), at  = 3 years was 0.15 with an estimated probability of diabetes-free survival at  = 3 years equal to 0.86 in the lifestyle intervention group and 0.71 in the placebo group.</s><s xml:id="_EyjQGH7">Using the proposed estimators, we examine the proportion of treatment effect explained by three potential surrogate markers: change from baseline to  0 in log-transformed hemoglobin A1c (HBA1C), fasting plasma glucose, and total cholesterol.</s><s xml:id="_trZfPH2">Figure <ref type="figure">1b-d</ref> show the mean surrogate marker measurement at baseline and at 1 year postbaseline within each group for HBA1C, fasting plasma glucose, and total cholesterol, respectively.</s><s xml:id="_9KMvSwf">For all three markers, the average of the Prevention Program study R (,   ) R  (,   ) R  (,   ) Estimate 0.589 0.619 0.651 SE 0.105 0.115 0.248 95% CI (0.4,0.79) (0.4,0.84) (0.14,1.12)</s><s xml:id="_9WZfYay">Abbreviations: SE, standard error; CI, confidence interval.</s></p><p xml:id="_JgAmC9g"><s xml:id="_z68p2GZ">surrogate marker measurement decreased from baseline to 1 year for the lifestyle intervention group, while for the placebo the average either increased, stayed the same, or only slightly decreased.</s></p><p xml:id="_UCWdsQM"><s xml:id="_geg5ku7">Results from estimating the proportion of treatment effect explained by these potential surrogate markers using our proposed estimators are shown Table <ref type="table">3</ref>.</s><s xml:id="_sjv2rnM">As in the simulation study, a simple logistic regression model is used, as described in Section 3.2, for ().</s><s xml:id="_UdbpAu2">Using either the twostage estimator or two-stage weighted estimator, the surrogate information at 1 year postbaseline explains 59% to 62% of the treatment effect on 3-year diabetes-free survival.</s><s xml:id="_yzbuQ7N">The double-robust estimator produces a slightly higher estimate of 65.1% though with a larger standard error and wider CI, which is expected given the simulation results.</s><s xml:id="_wdNESxx">For all estimators, the lower bound of the CI is under 0.5 and thus, it would be reasonable to conclude that this surrogate information at year 1 postbaseline, even though it combines information from three different markers, is not an adequate surrogate for diabetes-free survival.</s><s xml:id="_yuag4ks">For comparison, fasting plasma glucose, HBA1C, and total cholesterol alone at 1 year explain 57.7%, 32.9%, and 40.3% of the treatment effect on 3-year diabetes-free survival using the nonparametric method of <ref type="bibr" target="#b30">Parast et al. (2017)</ref>.</s><s xml:id="_tjra9t2">Therefore, at 1 year postbaseline, all three markers together explain only marginally more than fasting plasma glucose alone, likely due to overlap in information across the markers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6" xml:id="_2nmzJRA">DISCUSSION</head><p xml:id="_suQEz5p"><s xml:id="_9CxTBUv">We have proposed an approach to define the proportion of the treatment effect explained by information on multiple surrogate markers available at  0 when the primary outcome is a time-to-event outcome subject to censoring.</s></p><p xml:id="_rRZR8mr"><s xml:id="_dkJWFtV">In addition, we have proposed three robust estimators to estimate this defined quantity, derived asymptotic properties of the proposed estimators, proposed associated variance estimates, and demonstrated good finite sample performance in simulation studies.</s><s xml:id="_CmZ8tw5">In comparing the proposed estimators to alternative estimators that completely rely on correct model specification, we demonstrate the robustness of our proposed estimators to model misspecification.</s><s xml:id="_yHNsgkR">While the majority of previous methodological work in surrogate marker research has focused on settings where only a single surrogate is being evaluated, it is more often the case that there are multiple potential surrogate markers available and thus, further development and use of methods to evaluate a set of markers are important.</s><s xml:id="_qAxDqBH">To our knowledge, this work is the first to present multiple robust estimators to quantify the proportion of the treatment effect explained by multiple surrogate markers in a time-to-event outcome setting.</s><s xml:id="_znpRvVu">An R package implementing the methods proposed in this article, named Rsurrogate, is available on GitHub; see Web Appendix F. In practice, there may be an interest in examining the difference in the proportion of the treatment effect explained by two different sets of surrogate markers (or a set of surrogate markers vs. a single surrogate alone).</s><s xml:id="_rh34hwR">Using our proposed estimators, one could calculate this difference and construct a CI based on the difference in respective perturbed estimates.</s><s xml:id="_KSRzVrM">For example, using the estimator R  (,  0 ) from the diabetes example, the difference in the proportion explained by the three surrogate markers versus fasting plasma glucose alone is 7% with a 95% CI of (-46%, 59%) for the difference, indicating no statistically significant evidence that the three markers together explain more than fasting plasma glucose alone.</s></p><p xml:id="_qRDUsVv"><s xml:id="_rgUDqK6">Further discussion of our use of weights obtained from the model () is important.</s><s xml:id="_HuNTbPB">We present these weights as being similar in idea to propensity score weights where the goal is to obtain weights that would balance two groups with respect to specified variables, here .</s><s xml:id="_qJpjaeW">This is reasonable given our form of Δ  (,  0 ) but it is important to note that these should certainly not be considered to be propensity score weights in the usual sense of the term, as  is measured after treatment randomization.</s><s xml:id="_6yNphup">In addition, the use of weights of this kind in surrogate marker work and more generally in the development of methods to estimate direct and indirect effects is not new <ref type="bibr" target="#b9">(Barsky et al., 2002;</ref><ref type="bibr" target="#b6">Athey et al., 2016;</ref><ref type="bibr" target="#b47">Zhu et al., 2016;</ref><ref type="bibr" target="#b7">Athey et al., 2018)</ref>.</s></p><p xml:id="_7zPrhXy"><s xml:id="_96facrt">For example, though not in a survival setting, <ref type="bibr" target="#b6">Athey et al. (2016)</ref> considered the use of a model for () and a conditional mean model to estimate the treatment effect on the primary outcome using only surrogate marker information, when the primary outcome is not measured and there are multiple surrogate markers.</s><s xml:id="_J8CRhbn">While their proposed approach does not suggest a method to assess the value of the potential surrogates (and cannot accommodate censoring), they demonstrate that when all needed assumptions hold, use of the surrogate via their proposed methods to estimate and test for a treatment effect can be more efficient than using the primary outcome itself.</s><s xml:id="_8sqgU6b">As another example, <ref type="bibr" target="#b9">Barsky et al. (2002)</ref> use a similar idea to propose a nonparametric alternative to the Blinder-Oaxaca decomposition, often used in economics, to identify how much of the wealth gap between Blacks and Whites can be attributed to differences in income.</s></p><p xml:id="_vr7xCtC"><s xml:id="_aEhkJfs">Our proposed approach does have some limitations.</s><s xml:id="_qEs4jer">First, we require a number of assumptions.</s><s xml:id="_6BXTkJs">These assumptions are needed to ensure that the defined proportion quantity is between 0 and 1 and to ensure that we are not in a surrogate paradox situation in which the treatment positively affects the surrogates, the surrogates and timeto-event outcome are positively associated, but the treatment negatively affects the time-to-event outcome <ref type="bibr" target="#b42">(Wang and Taylor, 2002;</ref><ref type="bibr" target="#b40">VanderWeele, 2013;</ref><ref type="bibr" target="#b30">Parast et al., 2017)</ref>.</s><s xml:id="_gdaYBJv">Though these are not unique to our proposal and are generally required assumptions in surrogate marker-related research, they are strong and untestable.</s><s xml:id="_reSnVks">Work is ongoing to determine ways in which one can either relax these assumptions or assess the sensitivity of our results to violations of these assumptions <ref type="bibr" target="#b17">(Elliott et al., 2015;</ref><ref type="bibr" target="#b41">Wang et al., 2020)</ref>.</s><s xml:id="_RTmCGAN">Second, given that our estimation approach involves kernel smoothing, we need a relatively large sample size in each treatment group.</s><s xml:id="_hr5S9yA">Our methods are not recommended for studies with a very small sample size.</s><s xml:id="_aUgxetY">Lastly, our methods are not directly applicable to settings in which one would like to quantify the proportion of treatment effect explained by a longitudinal surrogate marker(s) or in which the set of potential surrogate markers is highdimensional.</s><s xml:id="_thr3MCK">For settings with longitudinal marker, careful consideration is needed with respect to the choice of the working model to characterize the relationship between the trajectory of the marker and the outcome, the number of measurements needed for each subject, and the potential complication that an individual may be censored before  0 with a partially observed trajectory.</s><s xml:id="_BuF4yjc">For highdimensional setting, both models specified here, that is, (2) and model (6) for () would need to be adjusted to accommodate a high-dimensional .</s><s xml:id="_TMsBKy2">Future work on this topic may benefit from considering potentially building from recent work in the area of assessing high-dimensional</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>F</head><figDesc><div><p xml:id="_WqW897s"><s xml:id="_YUgQexa">Diabetes Prevention Program: (a) diabetes-free survival probability over time for the lifestyle intervention group and placebo group; (b) mean hemoglobin A1c measurements at baseline and 1 year postbaseline in each group; (c) mean fasting plasma glucose measurements at baseline and 1 year post-baseline in each group; (d) mean total cholesterol measurements at baseline and 1 year post-baseline in each group TA B L E 3 Results from examining the proportion of the treatment effect explained by the three potential surrogate markers: hemoglobin A1c, fasting plasma glucose, and total cholesterol, using data from the Diabetes</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_VhKC6fv"><s xml:id="_5Pq7MqP">Downloaded from https://academic.oup.com/biometrics/article/77/4/1315/7446198 by University of Iowa user on 14 August 2025</s></p></note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_ruCksXz"><p xml:id="_WPXfY2Y"><s xml:id="_Ywf8uqe">TA B L E 1 Performance of the proposed estimators of Δ  (,  0 ) under setting 1, when the conditional survival model is correctly specified, setting 2, when the model for () is correctly specified, and setting 3, when neither model is correctly specified</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UyX7H5W">S U P P O R T I N G I N F O R M AT I O N</head><p xml:id="_t3vM2km"><s xml:id="_a9VrpXb">Web Appendices referenced in Sections 3, 4, and 6 are available with this paper at the Biometrics website on Wiley Online Library.</s><s xml:id="_DptzV6h">For information about DPP data availability, see the Data Availability Statement Section.</s><s xml:id="_2XaVtVF">An R package implementing the methods proposed in this article, named Rsurrogate, is available on GitHub: <ref type="url" target="https://github.com/laylaparast/Rsurrogate">https://github.com/laylaparast/Rsurrogate</ref>.</s><s xml:id="_QhVJGuu">Specifically, the functions R.multiple.surv</s><s xml:id="_XakaZNS">and delta.multiple.surv</s><s xml:id="_e9TN9FS">implement all estimators described here and provides variance estimates and CIs.</s><s xml:id="_tZbrRDT">In addition, a zip file containing all code to replicate the simulation study and diabetes example is available with this paper at the Biometrics website on Wiley Online Library.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><surname>Mediators</surname></persName>
		</author>
		<idno type="DOI">10.1017/cbo9781316534205.004</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">mediators (</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><surname>Zhang</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang et al., 2016;</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><surname>Athey</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2018">2018. 2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Athey et al., 2018; Zhou et al., 2019).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><surname>Ata Ava I L A B I L I T Y S Tat E M E N T</surname></persName>
		</author>
		<ptr target="https://repository.niddk.nih.gov/studies/dpp/" />
		<title level="m" xml:id="_tNdGbZG">DPP data used in the example are publicly available through the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository</title>
		<imprint>
			<publisher>DPP</publisher>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">D ATA AVA I L A B I L I T Y S TAT E M E N T DPP data used in the example are publicly available through the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository (DPP, 2013): https: //repository.niddk.nih.gov/studies/dpp/.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Layla</forename><surname>O R C I D</surname></persName>
		</author>
		<author>
			<persName><surname>Parast</surname></persName>
		</author>
		<ptr target="https://orcid.org/0000-0002-7288-1009" />
		<imprint/>
	</monogr>
	<note type="raw_reference">O R C I D Layla Parast https://orcid.org/0000-0002-7288-1009</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_tcJCHx7">On the relationship between the causalinference and meta-analytic paradigms for the validation of surrogate endpoints</title>
		<author>
			<persName><forename type="first">A</forename><surname>R E F E R E N C E S Alonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Der Elst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Molenberghs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Burzykowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YcuTm8Y">Biometrics</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="15" to="24" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">R E F E R E N C E S Alonso, A., Van der Elst, W., Molenberghs, G., Buyse, M. and Burzykowski, T. (2015) On the relationship between the causal- inference and meta-analytic paradigms for the validation of sur- rogate endpoints. Biometrics, 71, 15-24.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main" xml:id="_hFNwAXP">Estimating treatment effects using multiple surrogates: the role of the surrogate score and the surrogate index</title>
		<author>
			<persName><forename type="first">S</forename><surname>Athey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chetty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Imbens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kang</surname></persName>
		</author>
		<idno type="DOI">10.3386/w26463</idno>
		<idno type="arXiv">arXiv:1603.09326</idno>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
	<note type="raw_reference">Athey, S., Chetty, R., Imbens, G. and Kang, H. (2016) Estimating treat- ment effects using multiple surrogates: the role of the surrogate score and the surrogate index. arXiv preprint arXiv:1603.09326.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_zETPMTR">Approximate residual balancing: debiased inference of average treatment effects in high dimensions</title>
		<author>
			<persName><forename type="first">S</forename><surname>Athey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Imbens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wager</surname></persName>
		</author>
		<idno type="DOI">10.1111/rssb.12268</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wJXBve8">Journal of the Royal Statistical Society: Series B (Statistical Methodology)</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="597" to="623" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Athey, S., Imbens, G.W. and Wager, S. (2018) Approximate residual balancing: debiased inference of average treatment effects in high dimensions. Journal of the Royal Statistical Society: Series B (Sta- tistical Methodology), 80, 597-623.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_ukkxAej">Doubly robust estimation in missing data and causal inference models</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Robins</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1541-0420.2005.00377.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U6YnHyE">Biometrics</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="962" to="973" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bang, H. and Robins, J.M. (2005) Doubly robust estimation in missing data and causal inference models. Biometrics, 61, 962-973.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_aWZ6pxE">Accounting for the black-white wealth gap: a nonparametric approach</title>
		<author>
			<persName><forename type="first">R</forename><surname>Barsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bound</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Charles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Lupton</surname></persName>
		</author>
		<idno type="DOI">10.1198/016214502388618401</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2f8ps3d">Journal of the American Statistical Association</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="663" to="673" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barsky, R., Bound, J., Charles, K.K. and Lupton, J.P. (2002) Account- ing for the black-white wealth gap: a nonparametric approach. Journal of the American Statistical Association, 97, 663-673.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_3vQznPQ">Contribution to the discussion of the paper by Dr Cox</title>
		<author>
			<persName><forename type="first">N</forename><surname>Breslow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9tk9YAm">Journal of the Royal Statistical Society, Series B</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="216" to="217" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Breslow, N. (1972) Contribution to the discussion of the paper by Dr Cox. Journal of the Royal Statistical Society, Series B, 34, 216-217.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<author>
			<persName><forename type="first">T</forename><surname>Burzykowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Molenberghs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
		<title level="m" xml:id="_2UVkMGs">The Evaluation of Surrogate Endpoints</title>
		<meeting><address><addrLine>New York, NY</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burzykowski, T., Molenberghs, G. and Buyse, M. (2005) The Evalua- tion of Surrogate Endpoints. New York, NY: Springer.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_74jMJN5">Criteria for the validation of surrogate endpoints in randomized experiments</title>
		<author>
			<persName><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Molenberghs</surname></persName>
		</author>
		<idno type="DOI">10.2307/2533853</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ezuZVdN">Biometrics</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1014" to="1029" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Buyse, M. and Molenberghs, G. (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics, 54, 1014-1029.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_z8nmsuX">Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Conlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Elliott</surname></persName>
		</author>
		<idno type="DOI">10.1093/biostatistics/kxt051</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DC7Ma2C">Biostatistics</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="266" to="283" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Conlon, A.S., Taylor, J.M. and Elliott, M.R. (2014) Surrogacy assess- ment using principal stratification when surrogate and outcome measures are multivariate normal. Biostatistics, 15, 266-283.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<author>
			<persName><surname>Dpp</surname></persName>
		</author>
		<ptr target="https://repository.niddk.nih.gov/studies/dpp/" />
		<title level="m" xml:id="_wvaDHXQ">Diabetes prevention program</title>
		<imprint>
			<date type="published" when="2013-09-18">2013. September 18, 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DPP (2013) Diabetes prevention program. https://repository.niddk. nih.gov/studies/dpp/. Accessed September 18, 2020.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_yW8ztZq">The diabetes prevention program: design and methods for a clinical trial in the prevention of type 2 diabetes</title>
		<author>
			<persName><surname>Dppg</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.22.4.623</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yznKrEP">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">623</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DPPG, (1999) The diabetes prevention program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care, 22, 623.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_HVqXN8G">Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</title>
		<author>
			<persName><surname>Dppg</surname></persName>
		</author>
		<idno type="PMID">11832527</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Dua9mwT">New England Journal of Medicine</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="393" to="403" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DPPG (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346, 393-403. PMID: 11832527.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_hejXzqx">Surrogacy marker paradox measures in meta-analytic settings</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Conlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kaciroti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
		<idno type="DOI">10.1093/biostatistics/kxu043</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7JucxCW">Biostatistics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="400" to="412" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elliott, M.R., Conlon, A.S., Li, Y., Kaciroti, N. and Taylor, J.M. (2015) Surrogacy marker paradox measures in meta-analytic settings. Biostatistics, 16, 400-412.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_B8K6Kev">Statistical validation of intermediate endpoints for chronic diseases</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Freedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Graubard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schatzkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4sb8MhP">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="167" to="178" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Freedman, L.S., Graubard, B.I. and Schatzkin, A. (1992) Statistical validation of intermediate endpoints for chronic diseases. Statis- tics in Medicine, 11, 167-178.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_wVqhCNj">Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sachs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Gilbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9Fc8AKt">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="381" to="395" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gabriel, E.E., Sachs, M.C. and Gilbert, P.B. (2015) Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints. Statistics in Medicine, 34, 381-395.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_bKpuB4j">An introduction to the augmented inverse propensity weighted estimator</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Glynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Quinn</surname></persName>
		</author>
		<idno type="DOI">10.1093/pan/mpp036</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RAkeaav">Political Analysis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="36" to="56" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Glynn, A.N. and Quinn, K.M. (2010) An introduction to the aug- mented inverse propensity weighted estimator. Political Analysis, 18, 36-56.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_ydBTZsQ">On inference in parametric survival data models</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Hjort</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_52pRrk3">International Statistical Review/Revue Internationale de Statistique</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="355" to="387" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hjort, N.L. (1992) On inference in parametric survival data mod- els. International Statistical Review/Revue Internationale de Statis- tique, 60, 355-387.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_Y4fYuxS">Comparing biomarkers as principal surrogate endpoints</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Gilbert</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1541-0420.2011.01603.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uVJpfR9">Biometrics</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1442" to="1451" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang, Y. and Gilbert, P.B. (2011) Comparing biomarkers as principal surrogate endpoints. Biometrics, 67, 1442-1451.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_gmF2Dka">The loss in efficiency from misspecifying covariates in proportional hazards regression models</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lagakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GUyajDB">Biometrika</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="156" to="160" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lagakos, S. (1988) The loss in efficiency from misspecifying covariates in proportional hazards regression models. Biometrika, 75, 156- 160.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_WgT64Kt">Improving propensity score weighting using machine learning</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Stuart</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.3782</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_spCbAhn">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="337" to="346" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee, B.K., Lessler, J. and Stuart, E.A. (2010) Improving propensity score weighting using machine learning. Statistics in Medicine, 29, 337-346.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_xmp8SDx">A method to assess the proportion of treatment effect explained by a surrogate endpoint</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Hoseyni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SdMzuVE">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="3175" to="3188" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, Z., Meredith, M.P. and Hoseyni, M.S. (2001) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine, 20, 3175-3188.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_dRGj9Ea">Estimating the proportion of treatment effect explained by a surrogate marker</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De Gruttola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ackgpre">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1515" to="1527" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lin, D., Fleming, T., De Gruttola, V. (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine, 16, 1515-1527.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_utNMhVG">Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Lunceford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davidian</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.1903</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tfa6ADU">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2937" to="2960" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lunceford, J.K. and Davidian, M. (2004) Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Statistics in Medicine, 23, 2937-2960.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<idno type="DOI">10.1037/e565642010-001</idno>
		<ptr target="https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/advances-emerging-opportunities-diabetes-research-strategic-planning-report" />
		<title level="m" xml:id="_Tza9F6Z">Advances and emerging opportunities in diabetes research: a strategic planning report of the Diabetes Mellitus Interagency Coordinating Committee</title>
		<imprint>
			<publisher>NIDDK</publisher>
			<date type="published" when="2011-09-18">2011. September 18, 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">NIDDK (2011) Advances and emerging opportunities in diabetes research: a strategic planning report of the Diabetes Mellitus Inter- agency Coordinating Committee. https://www.niddk.nih.gov/ about-niddk/strategic-plans-reports/advances-emerging- opportunities-diabetes-research-strategic-planning-report. Accessed September 18, 2020.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_JunB5Sy">Inconsistency of the misspecified proportional hazards model</title>
		<author>
			<persName><forename type="first">T</forename><surname>O'neill</surname></persName>
		</author>
		<idno type="DOI">10.1016/0167-7152(86)90091-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XVVmf6s">Statistics &amp; Probability Letters</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="219" to="222" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;neill, T. (1986) Inconsistency of the misspecified proportional haz- ards model. Statistics &amp; Probability Letters, 4, 219-222.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_Y6Yt7h4">Evaluating surrogate marker information using censored data</title>
		<author>
			<persName><forename type="first">L</forename><surname>Parast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.7220</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DZh2vU2">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1767" to="1782" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Parast, L., Cai, T. and Tian, L. (2017) Evaluating surrogate marker information using censored data. Statistics in Medicine, 36, 1767- 1782.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_kT2Dfkr">Robust estimation of the proportion of treatment effect explained by surrogate marker information</title>
		<author>
			<persName><forename type="first">L</forename><surname>Parast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Mcdermott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.6820</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DFJZDSQ">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1637" to="1653" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Parast, L., McDermott, M.M. and Tian, L. (2015) Robust estimation of the proportion of treatment effect explained by surrogate marker information. Statistics in Medicine, 35(10), 1637-1653.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_DQMfX29">Landmark estimation of survival and treatment effect in a randomized clinical trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Parast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.1080/01621459.2013.842488</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ggR6Rnd">Journal of the American Statistical Association</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="384" to="394" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Parast, L., Tian, L. and Cai, T. (2014) Landmark estimation of survival and treatment effect in a randomized clinical trial. Journal of the American Statistical Association, 109, 384-394.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_n8YuH3E">Surrogate endpoints in clinical trials: definition and operational criteria</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Prentice</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.4780080407</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e8gX8uB">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="431" to="440" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prentice, R.L. (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine, 8, 431-440.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_2WeCfEE">Estimation of the optimal surrogate based on a randomized trial</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Der Laan</surname></persName>
		</author>
		<idno type="DOI">10.1111/biom.12879</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mNucNHF">Biometrics</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1271" to="1281" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Price, B.L., Gilbert, P.B. and van der Laan, M.J. (2018) Estimation of the optimal surrogate based on a randomized trial. Biometrics, 74, 1271-1281.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_32XAbm5">Toward a curse of dimensionality appropriate (CODA) asymptotic theory for semi-parametric models</title>
		<author>
			<persName><forename type="first">J</forename><surname>Robins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ritov</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1097-0258(19970215)16:3&lt;285::aid-sim535&gt;3.0.co;2-#</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fzjWDnv">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="285" to="319" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Robins, J. and Ritov, Y. (1997) Toward a curse of dimensionality appropriate (CODA) asymptotic theory for semi-parametric mod- els. Statistics in Medicine, 16, 285-319.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_pXTZzsy">Improved double-robust estimation in missing data and causal inference models</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rotnitzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sued</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Robins</surname></persName>
		</author>
		<idno type="DOI">10.1093/biomet/ass013</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Hcfs2hf">Biometrika</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="439" to="456" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rotnitzky, A., Lei, Q., Sued, M. and Robins, J.M. (2012) Improved double-robust estimation in missing data and causal inference models. Biometrika, 99, 439-456.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><surname>Scott</surname></persName>
		</author>
		<title level="m" xml:id="_HP3tXXa">Multivariate Density Estimation</title>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Wiley</publisher>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scott, D. (1992) Multivariate Density Estimation. New York: Wiley.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_mXsJrw4">Univariate versus multivariate surrogates in the single-trial setting</title>
		<author>
			<persName><forename type="first">W</forename><surname>Van Der Elst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alonso Abad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Geys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meyvisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bijnens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sengupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Molenberghs</surname></persName>
		</author>
		<idno type="DOI">10.1080/19466315.2019.1575276</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hSRyHWj">Statistics in Biopharmaceutical Research</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Van der Elst, W., Alonso Abad, A., Geys, H., Meyvisch, P., Bijnens, L., Sengupta, R. and Molenberghs, G. (2019) Univariate versus mul- tivariate surrogates in the single-trial setting. Statistics in Biophar- maceutical Research, 11, 1-16.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main" xml:id="_uQUaKMa">Dynamic Prediction in Clinical Survival Analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Van Houwelingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Putter</surname></persName>
		</author>
		<idno type="DOI">10.1201/b11311</idno>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>CRC Press</publisher>
			<pubPlace>Boca Raton, FL</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Van Houwelingen, J. and Putter, H. (2012) Dynamic Prediction in Clin- ical Survival Analysis. Boca Raton, FL: CRC Press.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_DPvQKGM">Surrogate measures and consistent surrogates</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Vanderweele</surname></persName>
		</author>
		<idno type="DOI">10.1111/biom.12071</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mnwJJNZ">Biometrics</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="561" to="565" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">VanderWeele, T.J. (2013) Surrogate measures and consistent surro- gates. Biometrics, 69, 561-565.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_YYHvmCv">Model free approach to quantifying the proportion of treatment effect explained by a surrogate marker</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Parast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.1093/biomet/asz065</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_S9CBgB3">Biometrika</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="107" to="122" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, X., Parast, L., Tian, L. and Cai, T. (2020) Model free approach to quantifying the proportion of treatment effect explained by a surrogate marker. Biometrika, 107(1), 107-122.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_bwy9ACt">A measure of the proportion of treatment effect explained by a surrogate marker</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uexd83c">Biometrics</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="803" to="812" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, Y. and Taylor, J.M. (2002) A measure of the proportion of treat- ment effect explained by a surrogate marker. Biometrics, 58, 803- 812.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_re4Px6v">Statistical evaluation of biomarkers as surrogate endpoints: a literature review</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Weir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Walley</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.2319</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AZw7Jtb">Statistics in Medicine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="183" to="203" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Weir, C.J. and Walley, R.J. (2006) Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine, 25, 183-203.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_uazFQVa">The evaluation of multiple surrogate endpoints</title>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Zeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DsHDvpT">Biometrics</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="81" to="87" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xu, J. and Zeger, S.L. (2001) The evaluation of multiple surrogate end- points. Biometrics, 57, 81-87.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_dQVxjza">Estimating and testing high-dimensional mediation effects in epigenetic studies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Joyce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M2uknye">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3150" to="3154" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang, H., Zheng, Y., Zhang, Z., Gao, T., Joyce, B., Yoon, G., et al. (2016) Estimating and testing high-dimensional mediation effects in epigenetic studies. Bioinformatics, 32, 3150-3154.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_VTEPpW6">Estimation and inference for the indirect effect in high-dimensional linear mediation models</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_R3ABCgF">Biometrika</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="573" to="589" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhou, R., Wang, L. and Zhao, S. (2019) Estimation and inference for the indirect effect in high-dimensional linear mediation models. Biometrika, 107(3), 573-589.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_bzkm5rB">Estimating controlled direct effects of restrictive feeding practices in the early dieting in girls study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Coffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Savage</surname></persName>
		</author>
		<idno type="DOI">10.1111/rssc.12109</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nvYnudv">Journal of the Royal Statistical Society: Series C (Applied Statistics)</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="115" to="130" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhu, Y., Ghosh, D., Coffman, D.L. and Savage, J.S. (2016) Estimating controlled direct effects of restrictive feeding practices in the early dieting in girls study. Journal of the Royal Statistical Society: Series C (Applied Statistics), 65, 115-130.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
